Apellis Pharmaceuticals Inc. (APLS)’s Financial Results Comparing With Edge Therapeutics Inc. (NASDAQ:EDGE)

As Biotechnology businesses, Apellis Pharmaceuticals Inc. (NASDAQ:APLS) and Edge Therapeutics Inc. (NASDAQ:EDGE), are affected by compare. This especially applies to their profitability, institutional ownership, analyst recommendations, risk, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Apellis Pharmaceuticals Inc. N/A 0.00 109.30M -2.05 0.00
Edge Therapeutics Inc. N/A 0.00 51.69M -2.09 0.00

We can see in table 1 the earnings per share (EPS), gross revenue and valuation of Apellis Pharmaceuticals Inc. and Edge Therapeutics Inc.


Table 2 represents Apellis Pharmaceuticals Inc. (NASDAQ:APLS) and Edge Therapeutics Inc. (NASDAQ:EDGE)’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Apellis Pharmaceuticals Inc. 0.00% -62.1% -51.4%
Edge Therapeutics Inc. 0.00% -120.9% -81.4%


Apellis Pharmaceuticals Inc.’s Current Ratio and Quick Ratio are 14.9 and 14.9 respectively. The Current Ratio and Quick Ratio of its competitor Edge Therapeutics Inc. are 5.5 and 5.5 respectively. Apellis Pharmaceuticals Inc. therefore has a better chance of paying off short and long-term obligations compared to Edge Therapeutics Inc.

Insider and Institutional Ownership

Institutional investors owned 57.6% of Apellis Pharmaceuticals Inc. shares and 31.9% of Edge Therapeutics Inc. shares. 20.7% are Apellis Pharmaceuticals Inc.’s share owned by insiders. Competitively, 14.97% are Edge Therapeutics Inc.’s share owned by insiders.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Apellis Pharmaceuticals Inc. 17.21% 12.73% 1.64% -12.51% 28.52% -17.14%
Edge Therapeutics Inc. -31.11% -33.09% -45.09% -51.77% -94.96% -95.04%

For the past year Apellis Pharmaceuticals Inc. was less bearish than Edge Therapeutics Inc.


Apellis Pharmaceuticals Inc. beats Edge Therapeutics Inc. on 5 of the 6 factors.

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidates include APL-2 and APL-1, to treat paroxysmal nocturnal hemoglobinuria, geographic atrophy, intermediate age-related macular degeneration, and chronic obstructive pulmonary disease. The company develops APL-2 for subcutaneous injection, which is an injection into the tissue under the skin, and for intravitreal injection that is an injection into the eye, as well as APL-1 for inhaled administration. Apellis Pharmaceuticals, Inc. was founded in 2009 and is based in Crestwood, Kentucky.

Edge Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and seeks to commercialize hospital-based therapies for acute life-threatening neurological and other conditions. Its lead product includes EG-1962, a polymer-based microsphere used for the treatment of aneurysmal subarachnoid hemorrhage. The company is also developing EG-1964 for the management of chronic subdural hematoma as a prophylactic treatment to prevent recurrent bleeding on the surface of the brain. Edge Therapeutics, Inc. was founded in 2009 and is headquartered in Berkeley Heights, New Jersey.